U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07883512) titled 'EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)' on Oct. 12.
Brief Summary: The primary objective of this pilot study is to evaluate the feasibility and acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Supportive Care in Cancer
Intervention:
DRUG: Empagliflozin
Empagliflozin 10 milligrams (mg) taken by mouth once daily.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Virginia Commonwealth University
Disclaimer: Curated by HT S...